These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8726020)

  • 1. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.
    Bender AR; von Briesen H; Kreuter J; Duncan IB; Rübsamen-Waigmann H
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1467-71. PubMed ID: 8726020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles.
    Bender A; Schfer V; Steffan AM; Royer C; Kreuter J; Rübsamen-Waigmann H; von Briesen H
    Res Virol; 1994; 145(3-4):215-20. PubMed ID: 7800948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saquinavir plus ddC reduces deaths by more than two-thirds.
    J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):51. PubMed ID: 11363697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
    Johnson VA; Merrill DP; Chou TC; Hirsch MS
    J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HIV-1 in monocyte/macrophage cultures by 2',3'-dideoxycytidine-5'-triphosphate, free and in liposomes.
    Szebeni J; Wahl SM; Betageri GV; Wahl LM; Gartner S; Popovic M; Parker RJ; Black CD; Weinstein JN
    AIDS Res Hum Retroviruses; 1990 May; 6(5):691-702. PubMed ID: 2163269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on HIV protease inhibitors.
    Vella S
    AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3TC and saquinavir: we need them now.
    Baker R
    BETA; 1995 Sep; ():3. PubMed ID: 11362889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent new AIDS drugs underscore promise of combination therapy.
    AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies.
    Dodiya SS; Chavhan SS; Sawant KK; Korde AG
    J Microencapsul; 2011; 28(6):515-27. PubMed ID: 21728760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase.
    Craig JC; Duncan IB; Hockley D; Grief C; Roberts NA; Mills JS
    Antiviral Res; 1991 Dec; 16(4):295-305. PubMed ID: 1810306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells.
    Ece Gamsiz D; Shah LK; Devalapally H; Amiji MM; Carrier RL
    Biotechnol Bioeng; 2008 Dec; 101(5):1072-82. PubMed ID: 18553495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS.
    Shah LK; Amiji MM
    Pharm Res; 2006 Nov; 23(11):2638-45. PubMed ID: 16969696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
    Katlama C; Pellegrin JL; Lacoste D; Aquilina C; Raffi F; Pialoux G; Vittecoq D; Raguin G; Lantz O; Mouroux M; Calvez V; Trylesinski A; Montestruc F; Dohin E; Goehrs JM; Delfraissy JF
    HIV Med; 2001 Jan; 2(1):20-6. PubMed ID: 11737372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine-5'-triphosphate-loaded erythrocytes.
    Magnani M; Rossi L; Fraternale A; Silvotti L; Quintavalla F; Piedimonte G; Matteucci D; Baldinotti F; Bendinelli M
    AIDS Res Hum Retroviruses; 1994 Sep; 10(9):1179-86. PubMed ID: 7826702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems.
    Ramana LN; Sharma S; Sethuraman S; Ranga U; Krishnan UM
    Biochim Biophys Acta; 2014 Jan; 1840(1):476-84. PubMed ID: 24121104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting.
    Schäfer V; von Briesen H; Andreesen R; Steffan AM; Royer C; Tröster S; Kreuter J; Rübsamen-Waigmann H
    Pharm Res; 1992 Apr; 9(4):541-6. PubMed ID: 1495900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy.
    Rusconi S; Merrill DP; Hirsch MS
    J Infect Dis; 1994 Dec; 170(6):1361-6. PubMed ID: 7527825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.